Results 51 to 60 of about 616,145 (212)
Journal of Medical Case Reports, 2011 Introduction Bronchial carcinomas in childhood and adolescence are extremely rare; only individual cases have been reported previously. Case presentation We report on a 16-year-old Caucasian German boy with non-small cell lung carcinoma (squamous cell ...
Haffner Dieter +2 more
doaj +1 more source
Arsenic trioxide suppresses tumour growth in squamous cell lung carcinoma [PDF]
, 2015 This journal suppl. entitled: 20th Medical Research Conference; Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong KongINTRODUCTION: Squamous cell lung carcinoma (SCC) belongs to the second most common subtype in non–small ...
Ho, JCM, Lam, SK, Leung, LL
core
A Case of Advanced Lung Squamous Cell Carcinoma with CLIP1-ALK Fusion Gene
Chinese Journal of Lung Cancer, 2022 Anaplastic lymphoma kinase (ALK) fusion gene is an important tumor driver gene of non-small cell lung cancer, accounting for about 5% of patients with non-small cell lung cancer, of which 97% are patients with lung adenocarcinoma.
Yue YUAN +4 more
doaj +1 more source
Biomedicines, 2023 Background: Telomerase (human telomerase reverse transcriptase (hTERT) is considered a hallmark of cancer, being active in cancer cells but repressed in human somatic cells. As such, it has the potential to serve as a valid cancer biomarker.
Ofer Rotem +13 more
doaj +1 more source
Yin Yang 1 is associated with cancer stem cell transcription factors (SOX2, OCT4, BMI1) and clinical implication. [PDF]
, 2016 The transcription factor Yin Yang 1 (YY1) is frequently overexpressed in cancerous tissues compared to normal tissues and has regulatory roles in cell proliferation, cell viability, epithelial-mesenchymal transition, metastasis and drug/immune resistance.
Bonavida, Benjamin +2 more
core +2 more sources
Drug Resistance Mechanisms in Non-Small Cell Lung Carcinoma [PDF]
Journal of Cancer Research Updates, 2013 Lung cancer is the most commonly diagnosed cancer in the world. “Driver” and “passenger” mutations identified in lung cancer indicate that genetics play a major role in the development of the disease, progression, metastasis and response to therapy.
Wangari-Talbot, Janet +1 more
openaire +2 more sources
Frontiers in Immunology, 2023 SMARCA4-deficient non-small cell carcinoma is an aggressive neoplasm with poor outcome. Several studies have highlighted its immunochemistry, pathophysiology, and underlying mechanisms, but studies of its definite treatment are few.
Yun-Tzu Lin +10 more
doaj +1 more source
Biological functions and molecular mechanisms of LINC00961 in human cancer
All Life, 2023 Long non-coding RNAs (lncRNAs) are more than 200 bp in length and do not translate into functional proteins. They are involved in inhibiting cell growth, migration, and invasion, and in promoting apoptosis.
Kai Li +3 more
doaj +1 more source
Platinum based doublet cross over therapy for advanced stage non small cell lung cancer? A better survival option [PDF]
, 2012 Platinum based doublet chemotherapy namely the cisplatin/carboplatin based etopiside or gemcitabine therapy forms the therapy of choice, for patients with advanced non small cell carcinoma of the lung. Here we report two cases were unusual cross over was
Ghulam Hassan +3 more
core
Plasma microRNA Associated with EGFR-TKI Primary Resistance in Non-Small Cell Lung Cancer with EGFR-Mutation [PDF]
, 2016 背景 肺癌是目前全世界范围内发病率和死亡率较高的恶性肿瘤之一。按组织学分类，肺癌可以分为两大类：小细胞肺癌（smallcelllungcancer，SCLC）和非小细胞肺癌（nonsmallcelllungcancer，NSCLC），小细胞肺癌占所有病例的20%，其余80%左右为NSCLC，包括鳞癌、腺癌、大细胞癌等类型。手术、放疗以及化疗等多学科综合治疗是指南推荐的NSCLC的首选治疗方式。由于NSCLC早期的典型临床症状和体征并不明显，约2/3的NSCLC患者在确诊时已发展为中晚期，失去手术根治机会。
潘小艳
core